TransCode Therapeutics, Inc. Profile Avatar - Palmy Investing

TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage produc…

Biotechnology
US, Boston [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

TransCode Therapeutics, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

TransCode Therapeutics, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of TransCode Therapeutics, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of RNAZ's Analysis
CIK: 1829635 CUSIP: 89357L105 ISIN: US89357L3033 LEI: - UEI: -
Secondary Listings
RNAZ has no secondary listings inside our databases.